Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation.
Vincenzo RussoAndrea PacconeAnna RagoValeria MaddaloniDario IafuscoRiccardo ProiettiUmberto AtripaldiAntonio D'OnofrioPaolo GolinoGerardo NigroPublished in: Journal of blood medicine (2020)
We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial determinations of apixaban plasma concentration (at 2, 6, 12, 24 hrs after intake) showing drug levels within reference range, even when the patient lose weight.
Keyphrases
- atrial fibrillation
- weight loss
- weight gain
- body mass index
- bariatric surgery
- oral anticoagulants
- physical activity
- direct oral anticoagulants
- catheter ablation
- left atrial
- venous thromboembolism
- left atrial appendage
- metabolic syndrome
- heart failure
- case report
- obese patients
- type diabetes
- adipose tissue
- percutaneous coronary intervention
- insulin resistance
- emergency department
- coronary artery disease
- acute coronary syndrome
- skeletal muscle